Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF

BACKGROUND: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild(®)) is a guideline-recommended regimen for HIV treatment-naïve patients and a switch option for virologically suppressed patients. OBJECTIVE: The purpose of this analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Anthony, Garner, Will, Pozniak, Anton, Berenguer, Juan, Speck, Rebecca M., Bender, Randall, Nguyen, Thai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529476/
https://www.ncbi.nlm.nih.gov/pubmed/26045359
http://dx.doi.org/10.1007/s40271-015-0129-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529476/
https://www.ncbi.nlm.nih.gov/pubmed/26045359
http://dx.doi.org/10.1007/s40271-015-0129-9

Ejemplares similares